Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BOOST-RCC
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
- NCT06284564 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Standard
We haven't built an HCP commentary report on BOOST-RCC (evolocumab plus nivolumab in metastatic renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BOOST-RCC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 5 | |
| X threads | 4 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Evolocumab; Nivolumab
- Arms
- Evolocumab + Nivolumab · Experimental
- Enrollment
- 10
- Primary outcomes
- Safety and adverse events (AEs)
- Sponsor
- M.D. Anderson Cancer Center with Bristol-Myers Squibb, Cancer Prevention Research Institute of Texas, United States Department of Defense
- Start
- Aug 7, 2024
- Primary completion
- Oct 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06284564 · updated Oct 15, 2026